Epidemiologic and Molecular Prognostic Review of Glioblastoma

Glioblastoma multiforme (GBM) is the most common and aggressive primary central nervous system malignancy with a median survival of 15 months. The average incidence rate of GBM is 3.19/100,000 population, and the median age of diagnosis is 64 years. Incidence is higher in men and individuals of white race and non-Hispanic ethnicity. Many genetic and environmental factors have been studied in GBM, but the majority are sporadic, and no risk factor accounting for a large proportion of GBMs has been identified. However, several favorable clinical prognostic factors are identified, including younger age at diagnosis, cerebellar location, high performance status, and maximal tumor resection. GBMs comprise of primary and secondary subtypes, which evolve through different genetic pathways, affect patients at different ages, and have differences in outcomes. We report the current epidemiology of GBM with new data from the Central Brain Tumor Registry of the United States 2006 to 2010 as well as demonstrate and discuss trends in incidence and survival. We also provide a concise review on molecular markers in GBM that have helped distinguish biologically similar subtypes of GBM and have prognostic and predictive value. Cancer Epidemiol Biomarkers Prev; 23(10); 1985–96. ©2014 AACR.

[1]  S. Leenstra,et al.  Genetic sub‐types of human malignant astrocytoma correlate with survival , 1998, International journal of cancer.

[2]  T. Holland-Letz,et al.  ATRX loss refines the classification of anaplastic gliomas and identifies a subgroup of IDH mutant astrocytic tumors with better prognosis , 2013, Acta Neuropathologica.

[3]  W. Curry,et al.  Racial, ethnic and socioeconomic disparities in the treatment of brain tumors , 2009, Journal of Neuro-Oncology.

[4]  R. Mirimanoff,et al.  Radiotherapy and temozolomide for newly diagnosed glioblastoma: recursive partitioning analysis of the EORTC 26981/22981-NCIC CE3 phase III randomized trial. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[5]  P. Kleihues,et al.  Genetic pathways to primary and secondary glioblastoma. , 2007, The American journal of pathology.

[6]  R. McLendon,et al.  Altered Telomeres in Tumors with ATRX and DAXX Mutations , 2011, Science.

[7]  Douglas C. Miller,et al.  Preferential Inactivation of the p53 Tumor Suppressor Pathway and Lack of EGFR Amplification Distinguish de novo High Grade Pediatric Astrocytomas from de novo Adult Astrocytomas , 2000, Brain pathology.

[8]  R. Mirimanoff,et al.  Presence of an oligodendroglioma-like component in newly diagnosed glioblastoma identifies a pathogenetically heterogeneous subgroup and lacks prognostic value: central pathology review of the EORTC_26981/NCIC_CE.3 trial , 2012, Acta Neuropathologica.

[9]  Veit Rohde,et al.  EXTENT OF RESECTION AND SURVIVAL IN GLIOBLASTOMA MULTIFORME: IDENTIFICATION OF AND ADJUSTMENT FOR BIAS , 2008, Neurosurgery.

[10]  Melissa Bondy,et al.  Epidemiology of primary brain tumors: current concepts and review of the literature. , 2002, Neuro-oncology.

[11]  Patrizia Frei,et al.  Use of mobile phones and risk of brain tumours: update of Danish cohort study , 2011, BMJ : British Medical Journal.

[12]  R. Wilson,et al.  Identification of a CpG island methylator phenotype that defines a distinct subgroup of glioma. , 2010, Cancer cell.

[13]  B. Tran,et al.  Survival comparison between glioblastoma multiforme and other incurable cancers , 2010, Journal of Clinical Neuroscience.

[14]  H. Jürgens,et al.  Pediatric high-grade astrocytomas show chromosomal imbalances distinct from adult cases. , 2001, The American journal of pathology.

[15]  R. Weichselbaum,et al.  Improved survival time trends for glioblastoma using the SEER 17 population-based registries , 2012, Journal of Neuro-Oncology.

[16]  R. McLendon,et al.  IDH1 and IDH2 mutations in gliomas. , 2009, The New England journal of medicine.

[17]  G. Giles,et al.  Role of medical history in brain tumour development. Results from the international adult brain tumour study , 1999, International journal of cancer.

[18]  V. Beral,et al.  Mobile phone use and risk of brain neoplasms and other cancers: prospective study. , 2013, International journal of epidemiology.

[19]  R. Fimmers,et al.  Prognostic Significance of Molecular Markers and Extent of Resection in Primary Glioblastoma Patients , 2009, Clinical Cancer Research.

[20]  Z L Gokaslan,et al.  A multivariate analysis of 416 patients with glioblastoma multiforme: prognosis, extent of resection, and survival. , 2001, Journal of neurosurgery.

[21]  D. Louis,et al.  Age-Dependent Prognostic Effects of Genetic Alterations in Glioblastoma , 2004, Clinical Cancer Research.

[22]  Anssi Auvinen,et al.  Mobile Phone Use and Incidence of Glioma in the Nordic Countries 1979–2008: Consistency Check , 2012, Epidemiology.

[23]  C. James,et al.  Gene amplification as a prognostic factor in primary and secondary high-grade malignant gliomas. , 1998, International journal of oncology.

[24]  Taofeek K Owonikoko,et al.  Lung cancer in elderly patients: an analysis of the surveillance, epidemiology, and end results database. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[25]  H. Wheeler,et al.  Elderly patients aged 65–75 years with glioblastoma multiforme may benefit from long course radiation therapy with temozolomide , 2014, Journal of Neuro-Oncology.

[26]  Christian HartmannBettina Patients with IDH1 wild type anaplastic astrocytomas exhibit worse prognosis than IDH1-mutated glioblastomas, and IDH1 mutation status accounts for the unfavorable prognostic effect of higher age: implications for classification of gliomas , 2010 .

[27]  A. Falini,et al.  Cancer esearch cular and Cellular Pathobiology ermal Growth Factor Receptor Expression Identifies ctionally and Molecularly Distinct Tumor-Initiating Cells uman Glioblastoma Multiforme and Is Required R Gliomagenesis , 2010 .

[28]  W. Curry,et al.  Racial/ethnic differences in survival among elderly patients with a primary glioblastoma , 2007, Journal of Neuro-Oncology.

[29]  W. Curran,et al.  Race and prognosis of brain tumor patients entering multicenter clinical trials. A report from the Radiation Therapy Oncology Group. , 1996, American journal of clinical oncology.

[30]  D. Louis WHO classification of tumours of the central nervous system , 2007 .

[31]  H. Fine,et al.  History of allergies and autoimmune diseases and risk of brain tumors in adults , 2002, International journal of cancer.

[32]  Howard Colman,et al.  MGMT promoter methylation is predictive of response to radiotherapy and prognostic in the absence of adjuvant alkylating chemotherapy for glioblastoma. , 2010, Neuro-oncology.

[33]  Maria Grazia Bruzzone,et al.  Methylation of O6-Methylguanine DNA Methyltransferase and Loss of Heterozygosity on 19q and/or 17p Are Overlapping Features of Secondary Glioblastomas with Prolonged Survival , 2007, Clinical Cancer Research.

[34]  F. Hochberg,et al.  Nonoccupational risk indicators of glioblastoma in adults , 1990, Journal of Neuro-Oncology.

[35]  TERT PROMOTER MUTATIONS OCCUR FREQUENTLY IN GLIOMAS AND A SUBSET OF TUMORS DERIVED FROM CELLS WITH LOW RATES OF SELF-RENEWAL , 2014 .

[36]  Guido Reifenberger,et al.  Pten signaling in gliomas. , 2002, Neuro-oncology.

[37]  J. Villano,et al.  Clinical presentation, histology, and treatment in 430 patients with primary tumors of the spinal cord, spinal meninges, or cauda equina. , 2010, Journal of neurosurgery. Spine.

[38]  Kenji Tada,et al.  Prognostic value of epidermal growth factor receptor in patients with glioblastoma multiforme. , 2003, Cancer research.

[39]  R. Stupp,et al.  Clinical Implications of Molecular Neuropathology and Biomarkers for Malignant Glioma , 2012, Current Neurology and Neuroscience Reports.

[40]  R. Fimmers,et al.  Lack of prognostic relevance of alterations in the epidermal growth factor receptor-transforming growth factor-alpha pathway in human astrocytic gliomas. , 1996, Journal of neurosurgery.

[41]  A. Marchetti,et al.  IDH1 mutations at residue p.R132 (IDH1R132) occur frequently in high‐grade gliomas but not in other solid tumors , 2009, Human mutation.

[42]  A. Verma MGMT Gene Silencing and Benefit From Temozolomide in Glioblastoma , 2006 .

[43]  P. Kleihues,et al.  IDH1 Mutations as Molecular Signature and Predictive Factor of Secondary Glioblastomas , 2009, Clinical Cancer Research.

[44]  Anthony Asher,et al.  Survival following surgery and prognostic factors for recently diagnosed malignant glioma: data from the Glioma Outcomes Project. , 2003, Journal of neurosurgery.

[45]  Susan M. Chang,et al.  Prognostic factors for survival of patients with glioblastoma: recursive partitioning analysis. , 2004, Neuro-oncology.

[46]  Caterina Giannini,et al.  Immunohistochemical Detection of EGFRvIII in High Malignancy Grade Astrocytomas and Evaluation of Prognostic Significance , 2004, Journal of neuropathology and experimental neurology.

[47]  Yuta Shibamoto,et al.  Influence of extent of surgery and tumor location on treatment outcome of patients with glioblastoma multiforme treated with combined modality approach , 2005, Journal of Neuro-Oncology.

[48]  Michael A. Vogelbaum,et al.  Neoplasms of the central nervous system , 2015 .

[49]  L. Ngo,et al.  Breast cancer among the oldest old: tumor characteristics, treatment choices, and survival. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[50]  R. McLendon,et al.  Frequent ATRX, CIC, FUBP1 and IDH1 mutations refine the classification of malignant gliomas , 2012, Oncotarget.

[51]  Faith Davis,et al.  Associations of high-grade glioma with glioma risk alleles and histories of allergy and smoking. , 2011, American journal of epidemiology.

[52]  Karl Schaller,et al.  Long-term survival of patients with glioblastoma multiforme (GBM) , 2013, Journal of Clinical Neuroscience.

[53]  H. Heinzl,et al.  Anti‐O6‐Methylguanine‐Methyltransferase (MGMT) Immunohistochemistry in Glioblastoma Multiforme: Observer Variability and Lack of Association with Patient Survival Impede Its Use as Clinical Biomarker * , 2008, Brain pathology.

[54]  A. Friedman,et al.  Outcome and prognostic factors in adult cerebellar glioblastoma , 2013, Journal of Clinical Neuroscience.

[55]  A. Sloan,et al.  Patterns of care and outcomes among elderly individuals with primary malignant astrocytoma. , 2008, Journal of neurosurgery.

[56]  D. Nelson,et al.  Influence of location and extent of surgical resection on survival of patients with glioblastoma multiforme: results of three consecutive Radiation Therapy Oncology Group (RTOG) clinical trials. , 1993, International journal of radiation oncology, biology, physics.

[57]  Daniel J Brat,et al.  Genetic Markers in Glioblastoma: Prognostic Significance and Future Therapeutic Implications: On: Impact of Genotype Morphology on the Prognosis of Glioblastoma. Schmidt MC Antweiler S, Urban N, et al. J Neuropathol Exp Neurol 2002;61:321–328. , 2003, Advances in anatomic pathology.

[58]  P Schaffer,et al.  Descriptive epidemiology of cerebral gliomas in France , 1997, Cancer.

[59]  J. Rey,et al.  Allelic status of 1p and 19q in oligodendrogliomas and glioblastomas: multiplex ligation-dependent probe amplification versus loss of heterozygosity. , 2009, Cancer genetics and cytogenetics.

[60]  J. Stockman,et al.  Everolimus for Subependymal Giant-Cell Astrocytomas in Tuberous Sclerosis , 2012 .

[61]  P. Kleihues,et al.  Genetic alterations and signaling pathways in the evolution of gliomas , 2009, Cancer science.

[62]  Susan M. Chang,et al.  Marital status, treatment, and survival in patients with glioblastoma multiforme , 2005, Cancer.

[63]  K. Hoang-Xuan,et al.  Prognostic impact of molecular markers in a series of 220 primary glioblastomas , 2006, Cancer.

[64]  A. Quiñones‐Hinojosa,et al.  Adult cerebellar glioblastoma: understanding survival and prognostic factors using a population-based database from 1973 to 2009. , 2013, World neurosurgery.

[65]  I. Petersen,et al.  Association of epidermal growth factor receptor gene amplification with loss of chromosome 10 in human glioblastoma multiforme. , 1992, Journal of neurosurgery.

[66]  哲治 中川内 Silencing effect of CpG island hypermethylation and histone modifications on O6-methylguanine-DNA methyltransferase (MGMT) gene expression in human cancer , 2004 .

[67]  David T. W. Jones,et al.  Driver mutations in histone H3.3 and chromatin remodelling genes in paediatric glioblastoma , 2012, Nature.

[68]  P. Kleihues,et al.  IDH1 mutations are early events in the development of astrocytomas and oligodendrogliomas. , 2009, The American journal of pathology.

[69]  F. Zanella,et al.  Fluorescence-guided surgery with 5-aminolevulinic acid for resection of malignant glioma: a randomised controlled multicentre phase III trial. , 2006, The Lancet. Oncology.

[70]  L. Hodges,et al.  Prevalence of Glioblastoma Multiforme in Subjects with Prior Therapeutic Radiation , 1992, The Journal of neuroscience nursing : journal of the American Association of Neuroscience Nurses.

[71]  L. Kleinberg Polifeprosan 20, 3.85% carmustine slow-release wafer in malignant glioma: evidence for role in era of standard adjuvant temozolomide , 2012, Core evidence.

[72]  M. Nikiforova,et al.  Diagnostic Use of IDH1/2 Mutation Analysis in Routine Clinical Testing of Formalin-Fixed, Paraffin-Embedded Glioma Tissues , 2009, Journal of neuropathology and experimental neurology.

[73]  P. Kleihues,et al.  Phenotype vs Genotype in the Evolution of Astrocytic Brain Tumors , 2000, Toxicologic pathology.

[74]  Andrey Korshunov,et al.  Frequent ATRX mutations and loss of expression in adult diffuse astrocytic tumors carrying IDH1/IDH2 and TP53 mutations , 2012, Acta Neuropathologica.

[75]  C. Horbinski What do we know about IDH1/2 mutations so far, and how do we use it? , 2013, Acta Neuropathologica.

[76]  D. Khullar,et al.  The influence of regional health system characteristics on the surgical management and receipt of post operative radiation therapy for glioblastoma multiforme , 2013, Journal of Neuro-Oncology.

[77]  P. Kleihues,et al.  TERT promoter mutations in primary and secondary glioblastomas , 2013, Acta Neuropathologica.

[78]  K. Black,et al.  Comparison of survival between cerebellar and supratentorial glioblastoma patients: surveillance, epidemiology, and end results (SEER) analysis. , 2013, Neurosurgery.

[79]  D. Miller,et al.  Microsatellite instability occurs in distinct subtypes of pediatric but not adult central nervous system tumors. , 2001, Cancer research.

[80]  P. Mckeever,et al.  Primary cerebellar glioblastoma multiforme , 2004, Journal of Neuro-Oncology.

[81]  S. Burma,et al.  Epidermal growth factor receptor in glioma: signal transduction, neuropathology, imaging, and radioresistance. , 2010, Neoplasia.

[82]  D. Haussler,et al.  The Somatic Genomic Landscape of Glioblastoma , 2013, Cell.

[83]  Susan M. Chang,et al.  Inherited variation in immune genes and pathways and glioblastoma risk , 2010, Carcinogenesis.

[84]  Christian Mawrin,et al.  Type and frequency of IDH1 and IDH2 mutations are related to astrocytic and oligodendroglial differentiation and age: a study of 1,010 diffuse gliomas , 2009, Acta Neuropathologica.

[85]  G. Somes,et al.  Racial differences in the incidence of gliomas: a retrospective study from Memphis, Tennessee. , 2002 .

[86]  S. Gabriel,et al.  Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1. , 2010, Cancer cell.

[87]  O. Bogler,et al.  A common mutant epidermal growth factor receptor confers enhanced tumorigenicity on human glioblastoma cells by increasing proliferation and reducing apoptosis. , 1996, Cancer research.

[88]  N. Rothman,et al.  Association between adult height, genetic susceptibility and risk of glioma. , 2012, International journal of epidemiology.

[89]  T. Jiang,et al.  Glioblastoma with an oligodendroglioma component: distinct clinical behavior, genetic alterations, and outcome. , 2012, Neuro-oncology.

[90]  Luca Regli,et al.  Clinical Trial Substantiates the Predictive Value of O-6-Methylguanine-DNA Methyltransferase Promoter Methylation in Glioblastoma Patients Treated with Temozolomide , 2004, Clinical Cancer Research.

[91]  Alexander R. Pico,et al.  Variants in the CDKN2B and RTEL1 regions are associated with high grade glioma susceptibility , 2009, Nature Genetics.

[92]  L. Liau,et al.  Cancer-associated IDH1 mutations produce 2-hydroxyglutarate , 2009, Nature.

[93]  Y. Suh,et al.  Glioblastoma with oligodendroglial component represents a subgroup of glioblastoma with high prevalence of IDH1 mutation and association with younger age , 2013, Journal of Neuro-Oncology.

[94]  P. Cassoni,et al.  MGMT promoter hypermethylation and its associations with genetic alterations in a series of 350 brain tumors , 2012, Journal of Neuro-Oncology.

[95]  Zhaoshi Jiang,et al.  Evidence for sequenced molecular evolution of IDH1 mutant glioblastoma from a distinct cell of origin. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[96]  W. Hall,et al.  Malignant gliomas of the cerebellum: An analytic review , 1998, Journal of Neuro-Oncology.

[97]  Paola Pisani,et al.  Genetic Pathways to Glioblastoma , 2004, Cancer Research.

[98]  Yan Ding,et al.  IDH mutations predict longer survival and response to temozolomide in secondary glioblastoma , 2012, Cancer science.

[99]  M. Nikiforova,et al.  1p/19q testing has no significance in the workup of glioblastomas , 2013, Neuropathology and applied neurobiology.

[100]  R. Mirimanoff,et al.  Outcome and prognostic factors in cerebellar glioblastoma multiforme in adults: a retrospective study from the Rare Cancer Network. , 2006, International journal of radiation oncology, biology, physics.

[101]  D. Brat,et al.  IDH1 mutations are common in malignant gliomas arising in adolescents: a report from the Children’s Oncology Group , 2010, Child's Nervous System.

[102]  A. Auvinen,et al.  An International Case-Control Study of Interleukin-4Rα, Interleukin-13, and Cyclooxygenase-2 Polymorphisms and Glioblastoma Risk , 2007, Cancer Epidemiology Biomarkers & Prevention.

[103]  A. Walker,et al.  Epidemiology of brain tumors , 1985, Neurology.

[104]  M. Weller,et al.  Geriatric neuro-oncology: from mythology to biology. , 2011, Current opinion in neurology.

[105]  Y. Kondo,et al.  The Global DNA Methylation Surrogate LINE-1 Methylation Is Correlated with MGMT Promoter Methylation and Is a Better Prognostic Factor for Glioma , 2011, PloS one.

[106]  B. Scheithauer,et al.  The 2007 WHO classification of tumours of the central nervous system , 2007, Acta Neuropathologica.

[107]  K. H. Mild,et al.  Case-control study of the association between malignant brain tumours diagnosed between 2007 and 2009 and mobile and cordless phone use , 2013, International journal of oncology.

[108]  Elisabeth Cardis,et al.  Brain tumour risk in relation to mobile telephone use: results of the INTERPHONE international case-control study. , 2010, International journal of epidemiology.

[109]  R. Plunkett,et al.  The impact of age and sex on the incidence of glial tumors in New York state from 1976 to 1995. , 2000, Journal of neurosurgery.

[110]  M. Röösli,et al.  Mobile phone use and risk of intracranial tumors: A consistency analysis , 2014, Bioelectromagnetics.

[111]  P. Brastianos,et al.  Prognostic and predictive value of epigenetic silencing of MGMT in patients with high grade gliomas: a systematic review and meta-analysis , 2011, Journal of Neuro-Oncology.

[112]  H. Donovan,et al.  Treatment disparities following the diagnosis of an astrocytoma , 2010, Journal of Neuro-Oncology.

[113]  M. Wrensch,et al.  Effects of antihistamine and anti‐inflammatory medication use on risk of specific glioma histologies , 2011, International journal of cancer.

[114]  J. Uhm An Integrated Genomic Analysis of Human Glioblastoma Multiforme , 2009 .

[115]  W. Cavenee,et al.  EGFR gene amplification ‐ rearrangement in human glioblastomas , 1995, International journal of cancer.

[116]  Candace Chisolm,et al.  Glioblastoma with Oligodendroglioma Component (GBM‐O): Molecular Genetic and Clinical Characteristics , 2013, Brain pathology.

[117]  C. James,et al.  Diversity and frequency of epidermal growth factor receptor mutations in human glioblastomas. , 2000, Cancer research.

[118]  M. Iori,et al.  Hypofractionated stereotactic radiation therapy for recurrent glioblastoma: single institutional experience , 2013, Radiation Oncology.

[119]  D. Louis,et al.  Specific genetic predictors of chemotherapeutic response and survival in patients with anaplastic oligodendrogliomas. , 1998, Journal of the National Cancer Institute.

[120]  Didier Frappaz,et al.  Temozolomide versus standard 6-week radiotherapy versus hypofractionated radiotherapy in patients older than 60 years with glioblastoma: the Nordic randomised, phase 3 trial. , 2012, The Lancet. Oncology.

[121]  J. Barnholtz-Sloan,et al.  CBTRUS statistical report: Primary brain and central nervous system tumors diagnosed in the United States in 2006-2010. , 2013, Neuro-oncology.

[122]  D Riddoch,et al.  Neoplasms of the central nervous system. , 1977, The Practitioner.

[123]  Gary L. Gallia,et al.  TERT promoter mutations occur frequently in gliomas and a subset of tumors derived from cells with low rates of self-renewal , 2013, Proceedings of the National Academy of Sciences.

[124]  Susan M. Chang,et al.  Glioblastoma Patients Epidermal Growth Factor Receptor , and Survival in Analysis of Complex Relationships between Age , p 53 , Updated , 2001 .

[125]  C. James,et al.  Amplified and rearranged epidermal growth factor receptor genes in human glioblastomas reveal deletions of sequences encoding portions of the N- and/or C-terminal tails. , 1992, Proceedings of the National Academy of Sciences of the United States of America.

[126]  Martin J. van den Bent,et al.  Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. , 2005, The New England journal of medicine.

[127]  R. Mirimanoff,et al.  Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. , 2009, The Lancet. Oncology.

[128]  S. Preston‐Martin,et al.  A population‐based description of glioblastoma multiforme in Los Angeles County, 1974–1999 , 2005, Cancer.

[129]  J. Abrams,et al.  Patterns of care and survival for patients with glioblastoma multiforme diagnosed during 2006. , 2012, Neuro-oncology.

[130]  M. Nikiforova,et al.  Paradoxical Relationship Between the Degree of EGFR Amplification and Outcome in Glioblastomas , 2012, The American journal of surgical pathology.

[131]  The glioblastoma multiforme in Georgia, 1977–1981 , 1985 .

[132]  Dana A. Sloane Cancer epidemiology in the United States: racial, social, and economic factors. , 2009, Methods in molecular biology.

[133]  C. James,et al.  PTEN mutation, EGFR amplification, and outcome in patients with anaplastic astrocytoma and glioblastoma multiforme. , 2001, Journal of the National Cancer Institute.

[134]  W. Hahn,et al.  Loss of ATRX, Genome Instability, and an Altered DNA Damage Response Are Hallmarks of the Alternative Lengthening of Telomeres Pathway , 2012, PLoS genetics.

[135]  L. Elveback,et al.  Neoplasms of the central nervous system , 1972, Neurology.

[136]  Y. Yonekawa,et al.  Promoter methylation of the DNA repair gene MGMT in astrocytomas is frequently associated with G:C --> A:T mutations of the TP53 tumor suppressor gene. , 2001, Carcinogenesis.

[137]  J. Barnholtz-Sloan,et al.  CBTRUS statistical report: primary brain and central nervous system tumors diagnosed in the United States in 2007-2011. , 2012, Neuro-oncology.

[138]  F. Davis,et al.  Conditional Survival of All Primary Brain Tumor Patients by Age, Behavior, and Histology , 2011, Neuroepidemiology.

[139]  J. Buckner,et al.  Conditional probability of long‐term survival in glioblastoma , 2012, Cancer.

[140]  C. López-Ginés,et al.  Primary glioblastomas with and without EGFR amplification: Relationship to genetic alterations and clinicopathological features , 2009, Neuropathology : official journal of the Japanese Society of Neuropathology.

[141]  Gabriele Schackert,et al.  Long-term survival with glioblastoma multiforme. , 2007, Brain : a journal of neurology.

[142]  K. Kinzler,et al.  Increased expression of the epidermal growth factor receptor gene in malignant gliomas is invariably associated with gene amplification. , 1987, Proceedings of the National Academy of Sciences of the United States of America.

[143]  A. Korshunov,et al.  The prognostic relevance of molecular alterations in glioblastomas for patients age < 50 years , 2005, Cancer.